BioSpace News Archive

AEON Biopharma, Inc. today announced that a group of existing stockholders have invested an additional $30 million into AEON in the form of an unsecured convertible note, bringing the total insider investment into the Company to $54.5 million since December 2021.

MediWound Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its recently re-submitted Biologics License Application (BLA) for NexoBrid ® for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.

Poseida Therapeutics, Inc. today announced it has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies.

2seventy bio, Inc . (Nasdaq: TSVT) announced today that members of the management team will participate in the following upcoming investor conferences.

Butterfly Network, Inc., a digital health company transforming care with handheld, whole-body ultrasound, announced financial results for the quarter ended June 30, 2022, and provided a business update.

Minerva Surgical, Inc. – The Uterine Health Company, focused on the treatment of Abnormal Uterine Bleeding, announced their Time To Talk social media campaign and local event series.

LYON, France, August3, 2022 - EDAP TMS SA, the global leader in robotic energy-based therapies, announced that it will release its financial results for the second quarter ended June 30th after the markets close on Wednesday, August 24th, 2022.

Neoleukin Therapeutics, Inc., today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 1 p.m. Eastern.

Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the addition of Matthew Kupferberg as the Company’s in-house General Counsel.

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report financial results for the second quarter ended June 30, 2022 on Monday, August 8, 2022 and will host a conference call and webcast at 4:30 p.m. Eastern Time that afternoon.